Catalyst Pharmaceuticals Inc   (CPRX)
Other Ticker:  
Price: $14.3500 $0.17 1.199%
Day's High: $14.4 Week Perf: 4.67 %
Day's Low: $ 14.16 30 Day Perf: 0.42 %
Volume (M): 1,482 52 Wk High: $ 18.22
Volume (M$): $ 21,267 52 Wk Avg: $14.08
Open: $14.21 52 Wk Low: $11.09

 Market Capitalization (Millions $) 1,529
 Shares Outstanding (Millions) 107
 Employees 94
 Revenues (TTM) (Millions $) 348
 Net Income (TTM) (Millions $) 62
 Cash Flow (TTM) (Millions $) -135
 Capital Exp. (TTM) (Millions $) 0

Catalyst Pharmaceuticals Inc
Catalyst Pharmaceuticals Inc is a biopharmaceutical company that focuses on the development and commercialization of drugs for rare neurological diseases. The company is headquartered in Coral Gables, Florida, and was founded in 200

The company's focus is on developing drugs for Lambert-Eaton Myasthenic Syndrome (LEMS), a rare autoimmune disorder that affects the neuromuscular junction. LEMS is characterized by muscle weakness and fatigue, and it affects only a small percentage of the population.

Catalyst Pharmaceuticals Inc. has one FDA-approved product on the market, Firdapse (amifampridine), which was approved by the FDA in November 2018. Firdapse is a potassium channel blocker that is used to treat adult patients with LEMS. The drug works to increase the release of acetylcholine, a neurotransmitter that is necessary for the normal function of the neuromuscular junction, thus improving muscle function in patients with LEMS.

The company's pipeline includes other drugs that target rare neurological diseases. CPP-115 is a GABA aminotransferase inhibitor, which is being developed for the treatment of epileptic encephalopathies, a group of rare and severe epileptic disorders.

Catalyst Pharmaceuticals Inc. has a strong financial position, with no debt and a cash balance of over $160 million as of the end of 2020. This stable financial position puts the company in a good position for the further development of its drug pipeline.

The company has faced some controversy in the past regarding the pricing of Firdapse, with critics arguing that the $375,000 per year price tag is too high. Catalyst Pharmaceuticals Inc. has defended its pricing, arguing that the drug is a life-changing treatment for patients with LEMS and is competitively priced compared to other rare disease treatments.

Overall, Catalyst Pharmaceuticals Inc. is a small but well-respected biopharmaceutical company focused on the development of drugs for rare neurological diseases. With its strong financial position and promising drug pipeline, it is poised for continued growth and success.

   Company Address: 355 Alhambra Circle Coral Gables 33134 FL
   Company Phone Number: 420-3200   Stock Exchange / Ticker: NASDAQ CPRX
   CPRX is expected to report next financial results on March 14, 2024.


Stock Performances by Major Competitors

5 Days Decrease / Increase
• View Complete Report

Clinical Study

Vamorolone Demonstrates Promising Long-Term Efficacy and Safety for Duchenne Muscular Dystrophy: An In-depth Review

Published Wed, Feb 21 2024 2:01 PM UTC

In recent developments, Catalyst Pharmaceuticals has announced the publication of Santhera Pharmaceuticals' VISION-DMD study results in the esteemed peer-reviewed journal, Neurology. The study elucidated the 48-week treatment outcomes of vamorolone, also known as AGAMREE, in patients suffering from Duchenne Muscular Dystrophy (DMD). These findings reinforce the drug's advant...


Catalyst Pharmaceuticals, Inc. Closes Successful Public Offering, Accelerating Growth Prospects

Published Tue, Jan 9 2024 9:05 PM UTC

Catalyst Pharmaceuticals, Inc. Successfully Closes Public Offering, Intensifying Investor Interest
Coral Gables, Florida - Catalyst Pharmaceuticals, Inc. (Nasdaq: CPRX) announced the completion of its underwritten public offering, wherein the company sold 10,000,000 shares of its common stock at a price of $15.00 per share. Additionally, Catalyst has granted the underwri...


Catalyst Pharmaceuticals Announces Pricing of Public Offering, Bolstering Shareholders' Confidence and Fueling Future Growth

Published Fri, Jan 5 2024 1:02 PM UTC

CORAL GABLES, Fla., Jan. 05, 2024 - Catalyst Pharmaceuticals, Inc. (Catalyst or the Company) (Nasdaq: CPRX) has made a significant move towards strengthening its financial position by announcing the pricing of an underwritten public offering of 10,000,000 shares of its common stock. With a public offering price of $15.00 per share, the company has successfully rais...


Catalyst Pharmaceuticals to Raise $150 Million through Public Offering, Fueling Growth Initiatives and Expanding Treatment Portfolio

Published Thu, Jan 4 2024 9:50 PM UTC

Catalyst Pharmaceuticals Inc. (Catalyst), a leading biopharmaceutical company specializing in rare disease treatments, has recently announced its plans to commence an underwritten public offering of $150,000,000 of its common stock. The offering, subject to market conditions, aims to provide Catalyst with additional capital to support its growth initiatives and fur...

Product Service News

Catalyst Pharmaceuticals Pursues Japanese Market with FIRDAPSE Application; Q3 Revenue Performance Outpaced

Published Mon, Dec 18 2023 11:30 AM UTC

Florida-based biopharmaceutical firm Catalyst Pharmaceuticals has taken significant steps to introduce its novel treatment for Lambert Eaton myasthenic syndrome (LEMS) into the Japanese market. Catalyst's partner, DyDo Pharma Inc., has submitted a New Drug Application (NDA) for FIRDAPSE (amifampridine) 10 mg tablets with Japan's Pharmaceuticals and Medical Devices Agenc...


Catalyst Pharmaceuticals Inc's Segments
• View Complete Report


About us


CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com